 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...196197198199200201202203204205206...235236» |
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 30, 2016
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Dec 2016 --> Apr 2017
- Trial primary completion date, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Sep 29, 2016
P2/3, N=716, Active, not recruiting, Sponsor: Krankenhaus Nordwest
Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Aug 2016 --> Dec 2016
- Trial primary completion date, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Sep 27, 2016
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2016 --> Dec 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- | veliparib (ABT-888) / AbbVie
Trial completion, Combination therapy: A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Sep 27, 2016
P1, N=47, Completed, Sponsor: AbbVie
Trial primary completion date: Jun 2016 --> Jun 2017 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Sep 26, 2016
P1/2, N=35, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Sep 2017
- || andecaliximab (GS-5745) / Gilead
Enrollment change, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 26, 2016
P1, N=250, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2016 --> Sep 2017 N=343 --> 250 | Trial primary completion date: Feb 2018 --> Jan 2019
- Avastin (bevacizumab) / Roche
Enrollment closed: DCE-MRI PET Bevacizumab Study in Rectal Cancer (clinicaltrials.gov) - Sep 26, 2016
P2, N=30, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
N=343 --> 250 | Trial primary completion date: Feb 2018 --> Jan 2019 Completed --> Active, not recruiting
- | Aphexda (motixafortide) / BioLineRx, Ayrmid
Enrollment open, Metastases: COMBAT: Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Sep 26, 2016
P2, N=30, Recruiting, Sponsor: BioLineRx, Ltd.
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- || Tecentriq (atezolizumab) / Roche
New P3 trial, Mismatch repair, Tumor mutational burden, PD(L)-1 Biomarker: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - Sep 22, 2016
P3, N=720, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Enrollment closed: Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer (clinicaltrials.gov) - Sep 22, 2016
P3, N=2000, Active, not recruiting, Sponsor: Hellenic Oncology Research Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | prexasertib (ACR-368) / Acrivon Therap
Phase classification, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Sep 22, 2016
P1b, N=185, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Phase classification: P1 --> P1b
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Trial primary completion date, Surgery, Metastases: COPERNICUS: Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Sep 21, 2016
P2, N=60, Completed, Sponsor: Cardiff University
Phase classification: P1 --> P1b Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Nov 2015
- | ensituximab (NEO-102) / ImmunityBio
Phase classification, Metastases: QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer (clinicaltrials.gov) - Sep 21, 2016
P2, N=90, Recruiting, Sponsor: Precision Biologics, Inc
Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Nov 2015 Phase classification: P1/2 --> P2
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial: Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer (clinicaltrials.gov) - Sep 21, 2016
P3, N=298, Not yet recruiting, Sponsor: Sun Yat-sen University
- Recentin (cediranib) / AstraZeneca
Trial completion, Enrollment change: Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers (clinicaltrials.gov) - Sep 20, 2016
P2, N=14, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P1/2 --> P2 Active, not recruiting --> Completed | N=36 --> 14
- | demcizumab (OMP-21M18) / Mereo Biopharma, BMS
Trial completion, Phase classification, Enrollment change, Trial primary completion date, IO biomarker, Metastases: A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2016
P1b, N=18, Completed, Sponsor: OncoMed Pharmaceuticals, Inc.
Active, not recruiting --> Completed | N=36 --> 14 Active, not recruiting --> Completed | Phase classification: P1 --> P1b | N=32 --> 18 | Trial primary completion date: Apr 2012 --> Feb 2011
- Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: FOCULM: FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 20, 2016
P2, N=138, Recruiting, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed | Phase classification: P1 --> P1b | N=32 --> 18 | Trial primary completion date: Apr 2012 --> Feb 2011 Trial primary completion date: Feb 2016 --> Feb 2018
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Sep 19, 2016
P2, N=66, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Feb 2016 --> Feb 2018 Trial primary completion date: Oct 2016 --> Apr 2017
- PF-04136309 / Pfizer
Trial completion, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 19, 2016
P1, N=44, Completed, Sponsor: Washington University School of Medicine
Trial primary completion date: Oct 2016 --> Apr 2017 Active, not recruiting --> Completed
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Sep 17, 2016
P3, N=870, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Trial primary completion date: Sep 2020 --> Mar 2019
- | Vectibix (panitumumab) / Amgen
New P2 trial: Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients (clinicaltrials.gov) - Sep 16, 2016
P2, N=180, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Sep 15, 2016
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2020 --> Mar 2019 Trial primary completion date: Jul 2016 --> Dec 2016
- Trial primary completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 15, 2016
P2, N=42, Recruiting, Sponsor: University of Florida
Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: Dec 2016 --> Jun 2017
- Enrollment closed, Trial primary completion date, Metastases: Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) - Sep 15, 2016
P2, N=32, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016
- crenolanib (ARO-002) / AROG
Trial primary completion date, Combination therapy: Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (clinicaltrials.gov) - Sep 12, 2016
P1, N=24, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: Nov 2016 --> Nov 2017
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
New trial, Surgery, Metastases: Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 12, 2016
P=N/A, N=8, Not yet recruiting, Sponsor: Thomas Jefferson University
- Enrollment open, Metastases: Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Sep 8, 2016
P2, N=100, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Nov 2016 --> Nov 2017 Not yet recruiting --> Recruiting
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Sep 8, 2016
P3, N=870, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | veliparib (ABT-888) / AbbVie
PARP Biomarker: S1513: FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 7, 2016
P2, N=143, Recruiting, Sponsor: National Cancer Institute (NCI)
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 6, 2016
P1, N=34, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Surgery: Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed (clinicaltrials.gov) - Sep 2, 2016
P3, N=1011, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- || davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors (clinicaltrials.gov) - Sep 2, 2016
P1, N=61, Recruiting, Sponsor: Cerulean Pharma Inc.
Active, not recruiting --> Completed N=36 --> 61 | Trial primary completion date: Apr 2016 --> Dec 2016
- |||| Jakafi (ruxolitinib) / Incyte
Enrollment open: AALL1521: A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 2, 2016
P2, N=170, Recruiting, Sponsor: Incyte Corporation
N=36 --> 61 | Trial primary completion date: Apr 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Real-world evidence, Real-world, Metastases: FOTAC: FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World Study (clinicaltrials.gov) - Sep 2, 2016
P2, N=50, Recruiting, Sponsor: Sun Yat-sen University
- || namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Combination therapy: NEXUS: Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 1, 2016
P2, N=108, Active, not recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> May 2017
- Biomarker, Trial primary completion date, Metastases: PAMELA70: Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 31, 2016
P2, N=72, Recruiting, Sponsor: Institut Cancerologie de l'Ouest
Trial primary completion date: Nov 2016 --> May 2017 Trial primary completion date: Jul 2016 --> Jul 2018
- || oxaliplatin / Generic mfg., irinotecan / Generic mfg.
New P3 trial: OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (clinicaltrials.gov) - Aug 30, 2016
P3, N=268, Not yet recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Surgery: Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer (clinicaltrials.gov) - Aug 30, 2016
P3, N=264, Completed, Sponsor: UNICANCER
Trial primary completion date: Jul 2016 --> Jul 2018 Recruiting --> Completed
- Enrollment closed, Metastases: FORTUNE: Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 30, 2016
P2, N=84, Active, not recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Completed Recruiting --> Active, not recruiting
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Phase classification, PD(L)-1 Biomarker, Metastases: Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) - Aug 30, 2016
P1b, N=9, Recruiting, Sponsor: Oncolytics Biotech
Recruiting --> Active, not recruiting Phase classification: P1 --> P1b
- || Oncaspar liquid (pegaspargase) / Servier
Clinical: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Aug 30, 2016
P3, N=5437, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
New P1 trial, Combination therapy, Metastases: A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors (clinicaltrials.gov) - Aug 29, 2016
P1, N=16, Completed, Sponsor: PharmaEngine
- |||| andecaliximab (GS-5745) / Gilead
Trial primary completion date, Metastases: GAMMA-1: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Aug 29, 2016
P3, N=430, Recruiting, Sponsor: Gilead Sciences
Phase classification: P1 --> P1b Trial primary completion date: Sep 2018 --> Jan 2019
- || New P2/3 trial, Metastases: Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer (clinicaltrials.gov) - Aug 28, 2016
P2/3, N=400, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- |||| Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial completion, Combination therapy, Metastases: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 26, 2016
P2, N=127, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Sep 2018 --> Jan 2019 Terminated --> Completed
- Avastin (bevacizumab) / Roche
Enrollment change, Trial withdrawal, Combination therapy, Metastases: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer. (clinicaltrials.gov) - Aug 24, 2016
P2, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
Terminated --> Completed N=37 --> 0 | Terminated --> Withdrawn
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Trial primary completion date, Metastases: S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma (clinicaltrials.gov) - Aug 23, 2016
P=N/A, N=583, Completed, Sponsor: Zhejiang University
N=37 --> 0 | Terminated --> Withdrawn Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Aug 2016
- || Graspa (eryaspase) / PHAXIAM Therap
Trial primary completion date, Metastases: Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma (clinicaltrials.gov) - Aug 23, 2016
P2, N=90, Recruiting, Sponsor: ERYtech Pharma
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Aug 2016 Trial primary completion date: Apr 2016 --> Dec 2016
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Trial primary completion date, Metastases: HCRN GI14-186: Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Aug 23, 2016
P2, N=30, Active, not recruiting, Sponsor: Safi Shahda, M.D.
Trial primary completion date: Apr 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2016
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Enrollment change, Combination therapy, Metastases: REGAIN: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (clinicaltrials.gov) - Aug 23, 2016
P2, N=2, Active, not recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2016 Recruiting --> Active, not recruiting | N=60 --> 2